Fujifilm corporation (20240099975). ANTI-TUMOR AGENT simplified abstract

ANTI-TUMOR AGENT

Organization Name

fujifilm corporation

Inventor(s)

Susumu Shimoyama of Cambridge MA (US)

Keiko Suzuki of Ashigarakami-gun (JP)

Mikinaga Mori of Ashigarakami-gun (JP)

Takeshi Matsumoto of Ashigarakami-gun (JP)

Shinji Nakayama of Ashigarakami-gun (JP)

Yasushi Morohashi of Ashigarakami-gun (JP)

Toshifumi Kimura of Ashigarakami-gun (JP)

ANTI-TUMOR AGENT - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240099975 titled 'ANTI-TUMOR AGENT

Simplified Explanation

The present invention provides an anti-tumor agent for curing cancer, which includes a liposome containing topotecan or a salt thereof, a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, and an inner water phase containing an ammonium salt. The topotecan is administered at a dose rate of 0.1 mg/mbody surface area to 10 mg/mbody surface area per administration.

• Liposome-based anti-tumor agent
• Contains topotecan or its salt
• Lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol
• Inner water phase contains an ammonium salt
• Administered at specific dose rates

Potential Applications

This technology can be applied in the field of oncology for the treatment of various types of cancer.

Problems Solved

This technology addresses the need for more effective anti-tumor agents with a remarkably excellent anti-tumor effect.

Benefits

The benefits of this technology include improved treatment outcomes for cancer patients and potentially reduced side effects compared to traditional treatments.

Potential Commercial Applications

The commercial applications of this technology include pharmaceutical companies developing and marketing this anti-tumor agent for cancer treatment.

Possible Prior Art

One possible prior art could be liposomal formulations of other chemotherapeutic agents for cancer treatment.

Unanswered Questions

1. What specific types of cancer can this anti-tumor agent effectively treat? 2. Are there any potential drug interactions or contraindications with this liposome-based agent that need to be considered?

Original Abstract Submitted

an object of the present invention is to provide an anti-tumor agent that exhibits a remarkably excellent anti-tumor effect. according to the present invention, there is provided an anti-tumor agent for curing cancer, the anti-tumor agent having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, the inner water phase contains an ammonium salt, and the topotecan or the salt thereof encompassed in the liposome is administered at a dose rate of 0.1 mg/mbody surface area to 10 mg/mbody surface area, in terms of topotecan per administration.